BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RBC Capital Reiterates Outperform Rating on Ideaya Biosciences (IDYA)
September 24, 2024 6:14 AM EDTRBC Capital analyst Gregory Renza reiterated an Outperform rating and $61.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments "Our key takeaway from IDYA's call this morning is a more refined blueprint for daro's regulatory path with positive ph.II data and the... More
Citi Reiterates Buy Rating on Ideaya Biosciences (IDYA)
September 23, 2024 4:34 PM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $58.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments "The Ph2 neoadjuvant UM data (including the prior IST) were in-line with our expectations for very substantial efficacy reflecting a 61% eye preservation rate among... More
Ideaya Biosciences (IDYA) PT Raised to $48 at Goldman Sachs
September 23, 2024 3:48 PM EDTGoldman Sachs analyst Corinne Jenkins raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $48.00 (from $47.00) while maintaining a Buy rating.
The analyst comments "DYA announced interim results from an ongoing Ph2 company-sponsored and investigator-sponsored study of darovasertib (daro) in neoadjuvant uveal melanoma (UM). Per the update, 49% (N=49) of patients achieved tumor shrinkage of 30%, while 61% (N=31) in the enucleation-evaluable cohort achieved eye preservation.... More
Ideaya Biosciences (IDYA) PT Lowered to $66 at Stifel
September 23, 2024 3:45 PM EDTStifel analyst Ben Burnett lowered the price target on Ideaya Biosciences (NASDAQ: IDYA) to $66.00 (from $68.00) while maintaining a Buy rating.
The analyst comments "We think the clinical data for darovasertib in the neoadjuvant setting are good, but that the stock... More
IDEAYA Biosciences (IDYA) Reports Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting
September 23, 2024 6:07 AM EDTIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma (UM) and a successful FDA Type C meeting on registrational trial design for regulatory approval in neoadjuvant UM.
"Darovasertib has demonstrated compelling preliminary clinical efficacy and a favorable AE profile in the neoadjuvant UM setting, with approximately 49% of patients demonstrating greater than 30% tumor shrinkage and importantly approximately 61% eye preservation rate for enucleation... More
